ABSTRACT

With the advent of targeted therapy for the treatment of metastatic renal cell carcinoma (mRCC), patients had the advantage of longer periods of medical treatment and longer survival. This has raised the challenges in the management of adverse events (AEs) associated with the sorafenib, sunitinib, pazopanib, bevasizumab in combi nation with interferon alpha, temsirolimus, and everolimus, which are, targeted agents approved in RCC. Suggestions for monitoring and managing AEs have been pub lished, but there are few consensus recommendations. Optimum monitoring and managing of AEs will increase the patient motivation and overall survival.